• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型 CB2 选择性大麻素受体配体的合理设计、合成及抗增殖活性研究:1,8-萘啶-2(1H)-酮骨架的探索。

Rational design, synthesis and anti-proliferative properties of new CB2 selective cannabinoid receptor ligands: an investigation of the 1,8-naphthyridin-2(1H)-one scaffold.

机构信息

Dipartimento di Scienze Farmaceutiche, Università di Pisa, via Bonanno 6, 56126 Pisa, Italy.

出版信息

Eur J Med Chem. 2012 Jun;52:284-94. doi: 10.1016/j.ejmech.2012.03.031. Epub 2012 Mar 24.

DOI:10.1016/j.ejmech.2012.03.031
PMID:22483967
Abstract

CB2 receptor ligands are becoming increasingly attractive drugs due to the potential role of this receptor in several physiopathological processes. Using our previously described series of 1,8-naphthyridin-2(1H)-on-3-carboxamides as a lead class, several nitrogen heterocyclic derivatives, characterized by different central cores, were synthesized and tested for their affinity toward the human CB1 and CB2 cannabinoid receptors. The obtained results suggest that the new series of quinolin-2(1H)-on-3-carboxamides, 4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamides and 1,2-dihydro-2-oxopyridine-3-carboxamides represent novel scaffolds very suitable for the development of promising CB2 ligands. Furthermore, the newly synthesized CB2 ligands inhibit proliferation of several cancer cell lines. In particular, it was demonstrated that in DU-145 cell line these ligands exert a CB2-mediated anti-proliferative action and decrease the CB2 receptor expression levels.

摘要

由于该受体在几种生理病理过程中的潜在作用,CB2 受体配体正成为越来越有吸引力的药物。使用我们之前描述的一系列 1,8-萘啶-2(1H)-酮-3-甲酰胺作为先导化合物,合成了具有不同中心核的几种氮杂环衍生物,并对其与人类 CB1 和 CB2 大麻素受体的亲和力进行了测试。获得的结果表明,新系列的喹啉-2(1H)-酮-3-甲酰胺、4-羟基-2-氧代-1,2-二氢-1,8-萘啶-3-甲酰胺和 1,2-二氢-2-氧代吡啶-3-甲酰胺代表了非常适合开发有前途的 CB2 配体的新型支架。此外,新合成的 CB2 配体抑制了几种癌细胞系的增殖。特别是,已经证明这些配体在 DU-145 细胞系中发挥 CB2 介导的抗增殖作用,并降低 CB2 受体表达水平。

相似文献

1
Rational design, synthesis and anti-proliferative properties of new CB2 selective cannabinoid receptor ligands: an investigation of the 1,8-naphthyridin-2(1H)-one scaffold.新型 CB2 选择性大麻素受体配体的合理设计、合成及抗增殖活性研究:1,8-萘啶-2(1H)-酮骨架的探索。
Eur J Med Chem. 2012 Jun;52:284-94. doi: 10.1016/j.ejmech.2012.03.031. Epub 2012 Mar 24.
2
Rational design, synthesis, and pharmacological properties of new 1,8-naphthyridin-2(1H)-on-3-carboxamide derivatives as highly selective cannabinoid-2 receptor agonists.新型1,8-萘啶-2(1H)-酮-3-甲酰胺衍生物作为高选择性大麻素-2受体激动剂的合理设计、合成及药理性质
J Med Chem. 2009 Jun 25;52(12):3644-51. doi: 10.1021/jm801563d.
3
Design, synthesis, and biological evaluation of new 1,8-naphthyridin-4(1H)-on-3-carboxamide and quinolin-4(1H)-on-3-carboxamide derivatives as CB2 selective agonists.新型1,8-萘啶-4(1H)-酮-3-甲酰胺和喹啉-4(1H)-酮-3-甲酰胺衍生物作为CB2选择性激动剂的设计、合成及生物学评价
J Med Chem. 2006 Oct 5;49(20):5947-57. doi: 10.1021/jm0603466.
4
New quinolone- and 1,8-naphthyridine-3-carboxamides as selective CB2 receptor agonists with anticancer and immuno-modulatory activity.新型喹诺酮和1,8-萘啶-3-甲酰胺作为具有抗癌和免疫调节活性的选择性CB2受体激动剂。
Eur J Med Chem. 2015 Jun 5;97:10-8. doi: 10.1016/j.ejmech.2015.04.034. Epub 2015 Apr 24.
5
CB2-selective cannabinoid receptor ligands: synthesis, pharmacological evaluation, and molecular modeling investigation of 1,8-Naphthyridin-2(1H)-one-3-carboxamides.CB2 选择性大麻素受体配体:1,8-萘啶-2(1H)-酮-3-甲酰胺的合成、药理学评价及分子模拟研究
J Med Chem. 2014 Nov 13;57(21):8777-91. doi: 10.1021/jm500807e. Epub 2014 Oct 15.
6
1-Aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamide: an effective scaffold for the design of either CB1 or CB2 receptor ligands.1-芳基-5-(1H-吡咯-1-基)-1H-吡唑-3-甲酰胺:设计 CB1 或 CB2 受体配体的有效支架。
Eur J Med Chem. 2011 Nov;46(11):5641-53. doi: 10.1016/j.ejmech.2011.09.037. Epub 2011 Sep 29.
7
Pharmacomodulations around the 4-oxo-1,4-dihydroquinoline-3-carboxamides, a class of potent CB2-selective cannabinoid receptor ligands: consequences in receptor affinity and functionality.围绕4-氧代-1,4-二氢喹啉-3-甲酰胺类进行的药物调制,一类强效CB2选择性大麻素受体配体:对受体亲和力和功能的影响。
J Med Chem. 2007 Nov 1;50(22):5471-84. doi: 10.1021/jm070387h. Epub 2007 Oct 4.
8
Cannabinoid receptor activation induces apoptosis through tumor necrosis factor alpha-mediated ceramide de novo synthesis in colon cancer cells.大麻素受体激活通过肿瘤坏死因子α介导的神经酰胺从头合成在结肠癌细胞中诱导凋亡。
Clin Cancer Res. 2008 Dec 1;14(23):7691-700. doi: 10.1158/1078-0432.CCR-08-0799.
9
Three-dimensional quantitative structure-selectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2.基于三维定量构效关系分析的大麻素受体 2 高选择性配体的合理设计。
Eur J Med Chem. 2011 Feb;46(2):547-55. doi: 10.1016/j.ejmech.2010.11.034. Epub 2010 Nov 27.
10
Design, synthesis and preliminary evaluation of (18)F-labelled 1,8-naphthyridin- and quinolin-2-one-3-carboxamide derivatives for PET imaging of CB2 cannabinoid receptor.用于CB2大麻素受体PET成像的(18)F标记的1,8-萘啶和喹啉-2-酮-3-甲酰胺衍生物的设计、合成及初步评价
Bioorg Med Chem Lett. 2015 Jun 15;25(12):2532-5. doi: 10.1016/j.bmcl.2015.04.055. Epub 2015 Apr 25.

引用本文的文献

1
Rational drug design of CB2 receptor ligands: from 2012 to 2021.CB2受体配体的合理药物设计:2012年至2021年
RSC Adv. 2022 Dec 8;12(54):35242-35259. doi: 10.1039/d2ra05661e. eCollection 2022 Dec 6.
2
Carbon dots for cancer nanomedicine: a bright future.用于癌症纳米医学的碳点:光明的未来。
Nanoscale Adv. 2021 Jul 8;3(18):5183-5221. doi: 10.1039/d1na00036e. eCollection 2021 Sep 14.
3
Synthesis and In Vitro Characterization of Selective Cannabinoid CB2 Receptor Agonists: Biological Evaluation against Neuroblastoma Cancer Cells.
合成和体外鉴定选择性大麻素 CB2 受体激动剂:针对神经母细胞瘤癌细胞的生物学评价。
Molecules. 2022 May 7;27(9):3019. doi: 10.3390/molecules27093019.
4
Non-Canonical Cannabinoid Receptors with Distinct Binding and Signaling Properties in Prostate and Other Cancer Cell Types Mediate Cell Death.非典型大麻素受体在前列腺和其他癌细胞类型中具有不同的结合和信号转导特性,介导细胞死亡。
Int J Mol Sci. 2022 Mar 11;23(6):3049. doi: 10.3390/ijms23063049.
5
Antitumor Cannabinoid Chemotypes: Structural Insights.抗肿瘤大麻素化学型:结构见解
Front Pharmacol. 2019 May 31;10:621. doi: 10.3389/fphar.2019.00621. eCollection 2019.
6
Development of selective, fluorescent cannabinoid type 2 receptor ligands based on a 1,8-naphthyridin-2-(1)-one-3-carboxamide scaffold.基于1,8-萘啶-2-(1)-酮-3-甲酰胺支架的选择性荧光大麻素2型受体配体的开发。
Medchemcomm. 2018 Oct 23;9(12):2055-2067. doi: 10.1039/c8md00448j. eCollection 2018 Dec 1.
7
A Novel Naphthyridine Derivative, 3u, Induces Necroptosis at Low Concentrations and Apoptosis at High Concentrations in Human Melanoma A375 Cells.一种新型萘啶衍生物 3u 在低浓度时诱导人黑色素瘤 A375 细胞发生坏死性凋亡,在高浓度时诱导细胞发生凋亡。
Int J Mol Sci. 2018 Sep 29;19(10):2975. doi: 10.3390/ijms19102975.
8
Anti-Proliferative Properties and Proapoptotic Function of New CB2 Selective Cannabinoid Receptor Agonist in Jurkat Leukemia Cells.新型 CB2 选择性大麻素受体激动剂在 Jurkat 白血病细胞中的抗增殖特性和促凋亡功能。
Int J Mol Sci. 2018 Jul 4;19(7):1958. doi: 10.3390/ijms19071958.
9
Structure-Activity Relationship of Cannabis Derived Compounds for the Treatment of Neuronal Activity-Related Diseases.大麻素化合物治疗与神经元活动相关疾病的结构-活性关系。
Molecules. 2018 Jun 25;23(7):1526. doi: 10.3390/molecules23071526.
10
Polymer-Mediated Delivery of siRNAs to Hepatocellular Carcinoma: Variables Affecting Specificity and Effectiveness.聚合物介导的 siRNA 递送至肝细胞癌:影响特异性和有效性的变量。
Molecules. 2018 Mar 28;23(4):777. doi: 10.3390/molecules23040777.